Ligand Pharmaceuticals Competitors

Amgen (NASDAQ:AMGN) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Risk & Volatility

Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 10.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Amgen and Ligand Pharmaceuticals, as reported by MarketBeat.

Amgen presently has a consensus target price of $259.4091, indicating a potential upside of 4.20%. Ligand Pharmaceuticals has a consensus target price of $215.60, indicating a potential upside of 40.51%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ligand Pharmaceuticals is more favorable than Amgen.

Profitability

This table compares Amgen and Ligand Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Amgen and Ligand Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Ligand Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Ligand Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Volatility & Risk

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 10.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Gilead Sciences and Ligand Pharmaceuticals, as reported by MarketBeat.com.

Gilead Sciences presently has a consensus target price of $97.2308, indicating a potential upside of 49.33%. Ligand Pharmaceuticals has a consensus target price of $215.60, indicating a potential upside of 40.51%. Given Gilead Sciences' higher possible upside, equities research analysts plainly believe Gilead Sciences is more favorable than Ligand Pharmaceuticals.

Profitability

This table compares Gilead Sciences and Ligand Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Gilead Sciences and Ligand Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Ligand Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Ligand Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vertex Pharmaceuticals and Ligand Pharmaceuticals, as reported by MarketBeat.com.

Vertex Pharmaceuticals presently has a consensus target price of $293.1250, indicating a potential upside of 37.39%. Ligand Pharmaceuticals has a consensus target price of $215.60, indicating a potential upside of 40.51%. Given Ligand Pharmaceuticals' higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares Vertex Pharmaceuticals and Ligand Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 10.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Ligand Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Earnings and Valuation

This table compares Ligand Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ligand Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ligand Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 40.51%. Regeneron Pharmaceuticals has a consensus price target of $637.2083, indicating a potential upside of 34.10%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Ligand Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 10.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Ligand Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Earnings and Valuation

This table compares Ligand Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Ligand Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ligand Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ligand Pharmaceuticals and Biogen, as reported by MarketBeat.

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 40.51%. Biogen has a consensus price target of $303.5517, indicating a potential upside of 13.19%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Biogen.

Profitability

This table compares Ligand Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

83.5% of Biogen shares are owned by institutional investors. 10.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Biogen beats Ligand Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Earnings and Valuation

This table compares Ligand Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ligand Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ligand Pharmaceuticals and Alexion Pharmaceuticals, as reported by MarketBeat.

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 40.51%. Alexion Pharmaceuticals has a consensus price target of $153.8636, indicating a potential downside of 0.74%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Ligand Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 10.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Alexion Pharmaceuticals beats Ligand Pharmaceuticals on 9 of the 14 factors compared between the two stocks.